Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191796 · ClinicalTrials.gov registry record · Phase 1
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06191796 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 25 participants.
The verdict
NCT06191796, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are: * The recommended doses (RDs) * The safety and tolerability * The PK and the preliminary efficacy
Interventions
- BIOLOGICAL Nivolumab
- DRUG zanzalintinib
- DRUG AB521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06191796
The ClinicalTrials.gov registry entry for NCT06191796 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT06191796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06191796 about?
NCT06191796 is a clinical study titled "Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)". The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims t...
What is the current status of trial NCT06191796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-01-25. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT06191796?
The interventions under investigation include: Nivolumab (BIOLOGICAL), zanzalintinib (DRUG), AB521 (DRUG).
Who is sponsoring clinical trial NCT06191796?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.